The Role of PD-1 and CTLA-4 Blockade in Immunotherapy: Mechanisms of Action and Therapeutic Efficacy in Overcoming Lung Cancer Immune Evasion [Accepted]
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases and small cell lung cancer (SCLC) representing a highly aggressive neuroendocrine subtype with poor prognosis. Tumor cells evade immune surveillance by co-opting immune checkpoint pathways, principally programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This review evaluates PD-1 and CTLA-4 blockade mechanisms and therapeutic potential in overcoming immune evasion in lung cancer.
A structured narrative literature review synthesized evidence from preclinical studies, landmark clinical trials including KEYNOTE-001 and IMpower133, biomarker investigations, and mechanistic research on PD-1/PD-L1 and CTLA-4 pathways in NSCLC and SCLC. PD-1 suppresses effector T cell activity and enhances regulatory T cell function within the tumor microenvironment, while CTLA-4 attenuates T cell priming through competitive B7 ligand binding. Immune escape is further mediated by HLA class I downregulation, impaired antigen presentation, immunosuppressive cytokine signaling, and tumor-infiltrating regulatory T cells. ICI monotherapy significantly improves overall survival in NSCLC with PD-L1 expression ≥50% versus platinum-based chemotherapy. First-line atezolizumab plus chemotherapy extended median overall survival to 12.3 versus 10.3 months in extensive-stage SCLC. Dual PD-1/CTLA-4 blockade produces synergistic antitumor responses; however, 70–85% of NSCLC patients develop primary or acquired resistance. PD-1 and CTLA-4 blockade has transformed the therapeutic landscape of lung cancer, yet resistance mechanisms, immune-related adverse events, and absence of validated predictive biomarkers remain critical challenges. Future research must prioritize combination strategies, novel checkpoint targets, and multifactorial biomarker panels to broaden clinical benefit.
References
Zhu M, Huang Y, Bender ME, Girard L, Kollipara R, Eglenen-Polat B, et al. Evasion of innate immunity contributes to small-cell lung cancer progression and metastasis. Cancer Research. 2021 Jan; https://www.semanticscholar.
Q H, Y L, Y H, J W, W B, C X, et al. Advances in molecular pathology and therapy of non-small cell lung cancer. 2025 June; https://europepmc.org/article/MED/40517166
Conforti F, Pala L, Pagan E, Bagnardi V, Pas TDD, Queirolo P, et al. Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion. Clinical Cancer Research. 2021 May; https://www.semanticscholar.
Pockley A, Vaupel P, Multhoff G, Geest J van. NK cell-based therapeutics for lung cancer. Expert Opinion on Biological Therapy. 2019 Nov; https://www.semanticscholar.
Affolter T, Llewellyn HP, Bartlett D, Zong Q, Xia S, Torti V, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE. 2019 May; https://www.semanticscholar.
6. Roy D, Gilmour C, Patnaik S, Wang L. Combinatorial blockade for cancer immunotherapy: Targeting emerging immune checkpoint receptors. Frontiers in Immunology. 2023 Oct; Available from: https://www.semanticscholar.
Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, et al. Therapeutic implications of tumor microenvironment in lung cancer: Focus on immune checkpoint blockade. Frontiers in Immunology. 2022 Jan; https://www.semanticscholar.
Wang S, Liu C, Yang C, Jin Y, Cui Q, Wang D, et al. PI3K/AKT/mTOR and PD‑1/CTLA‑4/CD28 pathways as key targets of cancer immunotherapy (review). Oncology Letters. 2024 Sept; https://www.semanticscholar.
Huang R, Francois A, McGray A, Miliotto AJ, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2016 Oct; https://www.semanticscholar
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde P, Hochmair M, et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: A phase 2 umbrella trial. Nature Medicine. 2024 Feb; https://www.semanticscholar.
Aden D, Zaheer S, Sureka N, Trisal M, Chaurasia J, Zaheer S. Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond. Pathology, Research and Practice. 2025 Mar; https://www.semanticscholar
Lee JB, Kim HR, Ha S. Immune checkpoint inhibitors in 10 years: Contribution of basic research and clinical application in cancer immunotherapy. Immune Network. 2022 Feb; https://www.semanticscholar.
Konen J, Wu H, Gibbons D. Immune checkpoint blockade resistance in lung cancer: Emerging mechanisms and therapeutic opportunities. TIPS - Trends in Pharmacological Sciences. 2024 May; https://www.semanticscholar
Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. Journal of Hematology & Oncology. 2024 July; https://www.semanticscholar.
Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2020 Dec; https://www.semanticscholar.
Wang H, Niu X, Jin Z, Zhang S, Fan R, Xiao H, et al. Immunotherapy resistance in non-small cell lung cancer: From mechanisms to therapeutic opportunities. Journal of experimental & clinical cancer research: CR. 2025 Aug; https://www.semanticscholar.
Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. Journal of Hematology & Oncology. 2024 July; https://www.semanticscholar.
Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, et al. Therapeutic implications of tumor microenvironment in lung cancer: Focus on immune checkpoint blockade. Frontiers in Immunology. 2022 Jan; https://www.semanticscholar.
Lahiri A, Maji A, Potdar PD, Singh N, Parikh PM, Bisht B, et al. Lung cancer immunotherapy: Progress, pitfalls, and promises. Molecular Cancer. 2023 Feb; https://doi.org/10.1186/s12943-023-01740-y
Tufail M, Jiang C, Li N. Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches. Signal Transduction and Targeted Therapy. 2025 July; https://www.semanticscholar.
Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class i antigen presentation. Frontiers in Immunology. 2021 Mar; https://doi.org/10.3389/fimmu.2021.636568
Perea F, Bernal M, Sánchez‐Palencia A, Carretero J, Torres CM, Bayarri C, et al. The absence of HLA class i expression in non‐small cell lung cancer correlates with the tumor tissue structure and the pattern of t cell infiltration. International Journal of Cancer . 2016 Nov; https://doi.org/10.1002/ijc.30489
Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, et al. Role of radiation therapy in modulation of the tumor stroma and microenvironment. Frontiers in Immunology . 2019 Feb; https://doi.org/10.3389/fimmu.2019.00193
Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduction and Targeted Therapy. 2024 July; https://doi.org/10.1038/s41392-024-01868-3
L W, Y L, C Z, P M, S Z, D J, et al. Regulatory t cells in homeostasis and disease: Molecular mechanisms and therapeutic potential. 2025 Oct; Available from: https://europepmc.org/article/MED/41087343
Turnis ME, Andrews LP, Vignali DAA. Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology. 2015 May; https://doi.org/10.1002/eji.201344413
Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A. Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: From bedside to bench and back. BioDrugs . 2025 Feb; https://www.semanticscholar
Anichini A, Perotti V, Sgambelluri F, Mortarini R. Immune escape mechanisms in non small cell lung cancer. Cancers. 2020 Dec; Available from: https://www.semanticscholar
Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Journal of Hematology & Oncology . 2019 June; https://www.semanticscholar
Hamilton G, Rath B. Immunotherapy for small cell lung cancer: Mechanisms of resistance. Expert Opinion on Biological Therapy. 2019 Mar; https://www.semanticscholar
Huang PW, Chang J. Immune checkpoint inhibitors win the 2018 nobel prize. Biomedical Journal. 2019 Oct; https://www.semanticscholar
JM F, MJ L. Development of immune checkpoint therapy for cancer. 2019 May; https://europepmc.org/article/MED/31068379
Chen YS, Shen CR. Immune checkpoint blockade therapy: The 2014 tang prize in biopharmaceutical science. Biomedical Journal. 2015; https://www.semanticscholar
Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Frontiers in Immunology . 2019 Dec; https://doi.org/10.3389/fimmu.2019.02965
Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis V. Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Frontiers in Immunology. 2023 June; https://www.semanticscholar.
Bertrand A, Kostine M, Barnetche T, Truchetet M, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Medicine . 2015 Sept; https://doi.org/10.1186/s12916-015-0455-8
Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling . 2022 Apr; https://doi.org/10.1186/s12964-022-00854-y
Kang SP, Gergich K, Lubiniecki G, Alwis DD, Chen C, Tice M, et al. Pembrolizumab KEYNOTE-001: An adaptive study leading to accelerated approval for two indications and a companion diagnostic. Annals of Oncology. 2017 Apr; https://www.semanticscholar.
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Molecular Cancer. 2024 May; https://doi.org/10.1186/s12943-024-02023-w
Qin W, Hu LP, Zhang X, Jiang S, Li J, Zhang Z, et al. The diverse function of PD-1/PD-l pathway beyond cancer. Frontiers in Immunology. 2019 Oct; https://doi.org/10.3389/fimmu.2019.02298
Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research . 2021 June; https://doi.org/10.1186/s13046-021-01987-7
Lee J, Kim E. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy. Frontiers in Oncology. 2023 July; https://www.semanticscholar
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications. 2016 Feb; https://doi.org/10.1038/ncomms10501
Konen J, Wu H, Gibbons D. Immune checkpoint blockade resistance in lung cancer: Emerging mechanisms and therapeutic opportunities. TIPS - Trends in Pharmacological Sciences. 2024 May; https://www.semanticscholar.
Wei S, Anang NAAS, Sharma R, Andrews M, Reuben A, Levine JH, et al. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences of the United States of America. 2019 Oct; https://www.semanticscholar.
Roy D, Gilmour C, Patnaik S, Wang L. Combinatorial blockade for cancer immunotherapy: Targeting emerging immune checkpoint receptors. Frontiers in Immunology. 2023 Oct; https://www.semanticscholar.
Kang SP, Gergich K, Lubiniecki G, Alwis DD, Chen C, Tice M, et al. Pembrolizumab KEYNOTE-001: An adaptive study leading to accelerated approval for two indications and a companion diagnostic. Annals of Oncology. 2017 Apr; https://www.semanticscholar.
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Molecular Cancer. 2024 May; https://doi.org/10.1186/s12943-024-02023-w
Huang PW, Chang J. Immune checkpoint inhibitors win the 2018 nobel prize. Biomedical Journal. 2019 Oct; https://www.semanticscholar.
Sánchez-Magraner L, Gumuzio J, Miles J, Quimi N, Prado PM del, Abad-Villar MT, et al. Functional engagement of the PD-1/PD-L1 complex but not PD-L1 expression is highly predictive of patient response to immunotherapy in non–small-cell lung cancer. Journal of Clinical Oncology . 2023 Feb; https://www.semanticscholar
Mandal K, Barik GK, Santra M. Overcoming resistance to anti-PD-L1 immunotherapy: Mechanisms, combination strategies, and future directions. Molecular Cancer. 2025 Oct; https://www.semanticscholar
Anichini A, Perotti V, Sgambelluri F, Mortarini R. Immune escape mechanisms in non-small cell lung cancer. Cancers. 2020 Dec; Available from: https://www.semanticscholar
Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, et al. Therapeutic implications of tumor microenvironment in lung cancer: Focus on immune checkpoint blockade. Frontiers in Immunology. 2022 Jan; https://www.semanticscholar
Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. Journal of Hematology & Oncology. 2019 June; https://www.semanticscholar.
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications. 2016 Feb; https://doi.org/10.1038/ncomms10501
He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Research. 2020 May; https://doi.org/10.1038/s41422-020-0343-4
Luo J, Cheng K, Ji X, Gao C, Zhu R, Chen J, et al. Anlotinib enhanced CD8+t cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer. Cancer Letters. 2024 Apr; https://www.semanticscholar
Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. Experimental & Molecular Medicine. 2018 Dec; https://doi.org/10.1038/s12276-018-0191-1
Jin R, Liu C, Zheng S, Wang X, Feng X, Li H, et al. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in east asian patients with non-small cell lung cancer. Cancer Biology and Medicine. 2020 Aug; https://www.semanticscholar
Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling. 2022 Apr; https://doi.org/10.1186/s12964-022-00854-y
Watanabe T, Ishino T, Ueda Y, Nagasaki J, Sadahira T, Dansako H, et al. Activated CTLA‐4‐independent immunosuppression of treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity. Cancer Science. 2023 Feb; https://www.semanticscholar
Bertrand A, Kostine M, Barnetche T, Truchetet M, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Medicine. 2015 Sept; https://doi.org/10.1186/s12916-015-0455-8
Paulsen E, Kilvaer T, Rakaee M, Richardsen E, Hald S, Andersen S, et al. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: Diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunology and Immunotherapy. 2017 July; org/paper/e7e9319c8e92d65cc13da22c873699d564ca5e63
Vackova J, Poláková I, Johari S, Šmahel M. CD80 expression on tumor cells alters tumor microenvironment and efficacy of cancer immunotherapy by CTLA-4 blockade. Cancers. 2021 Apr; org/paper/e1db766af18ccd661bf1f01b220b89089b532117
Choi H, Deng J, Li S, Silk T, Dong L, Brea E, et al. Pulsatile MEK inhibition improves anti-tumor immunity and t cell function in murine kras mutant lung cancer. Cell Reports. 2019 Apr; org/paper/470826c729d6cb4a01bccf81f74bad8782e0d3d1
Poon E, Mullins SR, Watkins A, Williams G, Koopmann J, Genova GD, et al. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. Journal of Immunotherapy for Cancer. 2017 Aug; org/paper/ac0bae09a323e584b6989df7d93e045abf73c489
Reeves KM, Song PN, Angermeier A, Manna DDD, Li Y, Wang J, et al. 18F-FMISO PET imaging identifies hypoxia and immunosuppressive tumor microenvironments and guides targeted evofosfamide therapy in tumors refractory to PD-1 and CTLA-4 inhibition. Clinical Cancer Research. 2021 Oct; org/paper/5e24ba138b3780874b61d36e94d7c48f21d9cb80
Lisi L, Lacal P, Martire M, Navarra P, Graziani G. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research. 2021 Nov; org/paper/543b2f2f9aa22926f43b3ff0bf5626fbc8ab47ed
Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. Journal of Hematology & Oncology. 2024 July; org/paper/045f88a17179585c949b065b1dcb1d3893c3ef04
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. New England Journal of Medicine. 2018 Sept; https://doi.org/10.1056/nejmoa1809064
Chen YS, Shen CR. Immune checkpoint blockade therapy: The 2014 tang prize in biopharmaceutical science. Biomedical Journal. 2015; org/paper/c3ae2fd61624f0adeff3a5bdcbf9784b0c21f50d
Gettinger S, Horn L, Gandhi L, Spigel DR, Antonia S, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. Journal of Clinical Oncology. 2015 Apr. https://doi.org/10.1200/jco.2014.58.3708
Kang SP, Gergich K, Lubiniecki G, Alwis DD, Chen C, Tice M, et al. Pembrolizumab KEYNOTE-001: An adaptive study leading to accelerated approval for two indications and a companion diagnostic. Annals of Oncology. 2017 Apr. https://www.semanticscholar.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Molecular Cancer. 2022 Jan. https://doi.org/10.1186/s12943-021-01489-2
Lisi L, Lacal P, Martire M, Navarra P, Graziani G. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research. 2021 Nov. org/paper/543b2f2f9aa22926f43b3ff0bf5626fbc8ab47ed
Bertrand A, Kostine M, Barnetche T, Truchetet M, Schaeverbeke T. Immune-related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Medicine. 2015 Sept. https://doi.org/10.1186/s12916-015-0455-8
Wei S, Anang NAAS, Sharma R, Andrews M, Reuben A, Levine JH, et al. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences of the United States of America. 2019Oct. org/paper/8b4b046b1adfa209d58bd7d1cdc8375fc2edf827
Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. Journal of Hematology & Oncology. 2024 July. org/paper/045f88a17179585c949b065b1dcb1d3893c3ef04
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental & Clinical Cancer Research. 2019 June https://doi.org/10.1186/s13046-019-1259-z
Robert C, Schachter J, Long GV, Arance A, Grob J, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine. 2015 Apr. https://doi.org/10.1056/nejmoa1503093
Chang L, Barroso‐Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocrine Reviews. 2018 Sept. https://doi.org/10.1210/er.2018-00006
Refbacks
- There are currently no refbacks.
____________________________________________________________________________________________________________________________________________
Health Dynamics || Open Access Journal || Online version only || Publisher: Knowledge Dynamics || ISSN: 3006-5518 (online) || Contact: healthdynamics.journal@gmail.com; +8801814901991; +6282136364408